Intravenous Zoledronate for a Patient with Paget’s Disease
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Paget’s disease (PD) of bone is characterized by increase of bone resorption by atypicalosteoclasts, followed by rapid new bone formation resulting in a disorganized mosaicbone. Although the pathophysiology is not fully understood, bisphosphonate, which isa potent anti-resorptive agent for treatment of osteoporosis, have been the most effec-tive agents available for the treatment of PD. We report a case of PD of bone in a 49-year-old woman patient, who was treated with intravenous zoledronate.
Abstract
Paget’s disease (PD) of bone is characterized by increase of bone resorption by atypicalosteoclasts, followed by rapid new bone formation resulting in a disorganized mosaicbone. Although the pathophysiology is not fully understood, bisphosphonate, which isa potent anti-resorptive agent for treatment of osteoporosis, have been the most effec-tive agents available for the treatment of PD. We report a case of PD of bone in a 49-year-old woman patient, who was treated with intravenous zoledronate.
참고문헌 (15)
- Lyles KW., "A clinical approach to diagnosis and management of Paget’s disease of bone", J Bone Miner Res., 16, pp.1379~1387 (2001)
- Cundy T., "Paget’s disease of bone", Clin Biochem., 45, pp.43~48 (2012)
- Ralston SH., "Pathogenesis and management of Paget’s disease of bone", Lancet., 372, pp.155~163 (2008)
- Deborah L. Galson, "Pathobiology of Paget’s Disease of Bone", 대한골대사학회지, 21(2), pp.85~97 (2014), 대한골대사학회
- Black DM., "Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis", N Engl J Med., 356, pp.1809~1822 (2007)
- Lyles KW., "Zoledronic acid and clinical fractures and mortality after hip fracture", N Engl J Med., 357, pp.1799~1809 (2007)
- Reid IR., "Intravenous zoledronic acid in postmenopausal women with low bone mineral density", N Engl J Med., 346, pp.653~661 (2002)
- Tucci JR., "Therapy with zoledronic acid, 5 mg, for a patient with Paget disease of bone", Endocr Pract., 14, pp.607~610 (2008)
- Boonen S., "Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance", J Intern Med., 264, pp.315~332 (2008)
- Kamatari M., "Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice : alendronate and risedronate", J Bone Miner Metab., 25, pp.302~309 (2007)
- Kertes J., "Factors contributing to compliance with osteoporosis medication", Isr Med Assoc J., 110, pp.207~213 (2008)
- Reid IR., "Comparison of a single infusion of zoledronic acid with risedronate for Paget’s disease", N Engl J Med., 353, pp.898~908 (2005)
- Hosking D., "Long-term control of bone turnover in Paget’s disease with zoledronic acid and risedronate", J Bone Miner Res., 22, pp.142~148 (2007)
- Lee YK., "Persistence with intravenous zoledronate in elderly patients with osteoporosis", Osteoporos Int., 23, pp.2329~2333 (2012)
- 이영균, "수술적 치료를 받은 고관절 주위 골절 환자에서의 정주용 Bisphosphonate : 단기 안전성에 대한 전향적 코호트 연구", Hip and Pelvis, 20(4), pp.305~310 (2008), 대한고관절학회